Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

PRX-07034

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
PRX-07034
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC21H29Cl2N3O4S
Molar mass490.44 g·mol−1
3D model (JSmol)
  • COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3
  • InChI=1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3
  • Key:BSLXKMCHXRCBIH-UHFFFAOYSA-N
  (verify)

PRX-07034 is aselective5-HT6 receptorantagonist.[1] It hascognition andmemory-enhancing properties and potently decreasesfood intake andbody weight in rodents.[1][2][3][4] PRX-07034 was under development byEpix Pharmaceuticals for the treatment ofobesity andcognitive impairment associated withAlzheimer's disease andschizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.[5][6][7]

References

[edit]
  1. ^ab"Science Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats".
  2. ^Fone KC (November 2008). "An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function".Neuropharmacology.55 (6):1015–22.doi:10.1016/j.neuropharm.2008.06.061.PMID 18655798.S2CID 35522597.
  3. ^"Science Links Japan | Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory".
  4. ^Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007)."Serotonergic drugs : effects on appetite expression and use for the treatment of obesity".Drugs.67 (1):27–55.doi:10.2165/00003495-200767010-00004.PMID 17209663.S2CID 46972692. Archived fromthe original on 2013-01-05. Retrieved2010-03-09.
  5. ^"PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials".
  6. ^"Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009".
  7. ^"Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction".

External links

[edit]
Stimulants
Amphetamines and
phenethylamines
Adrenergic agonists
Other
Cannabinoid
antagonists
GLP-1,GIP,and / or
glucagon agonists
DACRAs
5-HT2C
receptor agonists
Absorption inhibitors
Uncouplers
Others
Psychoanaleptics: Anti-dementia agents (ATC codeN06D and others)
AChE inhibitor medications
Other medications
ExperimentalBACE inhibitors
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=PRX-07034&oldid=1116389478"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp